Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.
Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C. Pagan F, et al. Among authors: wilmarth bm. J Parkinsons Dis. 2016 Jul 11;6(3):503-17. doi: 10.3233/JPD-160867. J Parkinsons Dis. 2016. PMID: 27434297 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Arellano J, Howard HH, Peyton M, Matar S, Liu X, Fowler AJ, Schwartz SL, Ahn J, Moussa C. Pagan FL, et al. Among authors: wilmarth b. Pharmacol Res Perspect. 2019 Mar 12;7(2):e00470. doi: 10.1002/prp2.470. eCollection 2019 Apr. Pharmacol Res Perspect. 2019. PMID: 30906562 Free PMC article. Clinical Trial.
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. Among authors: wilmarth b. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C. Pagan FL, et al. Among authors: wilmarth b. Mov Disord. 2021 Mar;36(3):740-749. doi: 10.1002/mds.28389. Epub 2020 Nov 20. Mov Disord. 2021. PMID: 33215762 Free PMC article. Clinical Trial.
CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease.
Fowler AJ, Ahn J, Hebron M, Chiu T, Ayoub R, Mulki S, Ressom H, Torres-Yaghi Y, Wilmarth B, Pagan FL, Moussa C. Fowler AJ, et al. Among authors: wilmarth b. Neurol Genet. 2021 Nov 12;7(6):e633. doi: 10.1212/NXG.0000000000000633. eCollection 2021 Dec. Neurol Genet. 2021. PMID: 34786477 Free PMC article.
Can sex influence the neurocognition of language? Evidence from Parkinson's disease.
Reifegerste J, Estabrooke IV, Russell LE, Veríssimo J, Johari K, Wilmarth B, Pagan FL, Moussa C, Ullman MT. Reifegerste J, et al. Among authors: wilmarth b. Neuropsychologia. 2020 Nov;148:107633. doi: 10.1016/j.neuropsychologia.2020.107633. Epub 2020 Sep 22. Neuropsychologia. 2020. PMID: 32971096 Free PMC article.